Intracavernosal therapy: When oral agents fail

Current Urology Reports

Volumn 2, Issue 6, 2001, Pages 468-472

  Nehra, Ajay ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Erectile Dysfunction; Papaverine; Phentolamine; Priapism; Vasoactive Intestinal Peptide

Indexed keywords

VASODILATOR AGENT;

DRUG EFFECT; HUMAN; IMPOTENCE; INJECTION; MALE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PENIS ERECTION; PHYSIOLOGY; REVIEW;

ADMINISTRATION, ORAL; HUMANS; IMPOTENCE; INJECTIONS; MALE; PENILE ERECTION; VASODILATOR AGENTS;

EID: 0035552292     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-001-0041-9     Document Type: Article

References (43)

1. Krane RJ, Goldstein I, Saenz de Tejada I: Impotence. N Engl J Med 1989, 321:1648–1659. DOI: 10.1056/NEJM198912143212406
2. National Institutes of Health: Impotence. National Institutes of Health Consensus Statement. JAMA 1993, 123:23–273.
3. Feldman HA, Goldstein I, Hatzichristou DG, et al.: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994, 151:54–61.
4. Benet AE, Melman A: The epidemiology of erectile dysfunction. Urol Clin North Am 1995, 22:699–709.
5. Jeremy JY, Mikhailidis DP: Cigarette smoking and erectile dysfunction. J R Soc Health 1998, 118:151–155.
6. Araujo AB, Durante R, Feldman HA, et al.: The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998, 60:458–465.
7. Laumann EO, Paik A, Rosen RC: Sexual dysfunction in the United States. Prevalence and predictors. JAMA 1999, 281:537–544. DOI: 10.1001/jama.281.6.537
8. Saenz de Tejada I: In the physiology of erection, signposts to impotence. Contemp Urol 1992, 7:52–68.
9. Andersson K-E, Wagner G: Physiology of erection. Physiol Rev 1995, 75:191–236.
10. Christ GJ: The penis as a vascular organ. Urol Clin North Am 1995, 22:727–745.
11. Burnett A: Nitric oxide in the penis: physiology and pathology. J Urol 1997, 157:320–324. DOI: 10.1016/S0022-5347(01)65369-2
12. Lue TF, Dahiya R: Molecular biology of erectile function and dysfunction. Mol Urol 1997, 1:55–64.
13. Porst H: The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996, 155:802–815. DOI: 10.1016/S0022-5347(01)66315-8
14. Linet OI, Orgrinc FG: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. Alprostadil Study Group. N Engl J Med 1996, 334:873–877. Excellent discussion of FDA-approved treatments for erectile dysfunction. DOI: 10.1056/NEJM199604043341401
15. Buvat J, Costa P, Morlier D, Lecocq B, et al.: Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorohydrate in chronic organic erectile dysfunction. J Urol 1998, 159:116–119. Report on a double-blind, multicenter study of Edex and PGE 1. DOI: 10.1016/S0022-5347(01)64030-8
16. Hellstrom WJ, Bennett AH, Gesundheit N, et al.: A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil. Urology 1996, 48:851–856. DOI: 10.1016/S0090-4295(96)00428-1
17. Padma-Nathan H, Hellstrom WHG, Kaiser FE, et al.: Treatment of men with erectile dysfunction with transurethral alpros-tadil. N Engl J Med 1997, 336:1–7. DOI: 10.1056/NEJM199701023360101
18. Lewis RW, Weldon K, Nemo K: Combined use of transurethral Alprostadil and an adjustable penile constriction band in men with erectile dysfunction: results from a multicenter trial [abstract 365]. Int J Impot Res 1998, 10(suppl 3):S49.
19. Sattar AA, Salpigides G, Vanderhaeghen JJ, et al.: Cavernous oxygen tension and smooth muscle fibers: relation and function. J Urol 1995, 154:1736–1739. DOI: 10.1016/S0022-5347(01)66772-7
20. Kim N, Vardi Y, Padma-Nathan H, et al.: Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J Clin Invest 1993, 91:437–442. DOI: 10.1172/JCI116220
21. Tarhan F, Kuyumcuoglu U, Kolsuz A, et al.: Cavernous oxygen tension in patients with erectile dysfunction. Int J Impot Res 1997, 9:149–153. DOI: 10.1038/sj.ijir.3900270
22. Moreland RB, Watkins MT, Nehra A, et al.: Oxygen tension modulates transforming growth factor-a1 expression and PGE production in human corpus cavernosum smooth muscle cells. Mol Urol 1998, 2:41–47.
23. Palmer LS, Valcic M, Melman A, et al.: Characterization of cyclic AMP accumulation in cultured human corpus caverno-sum smooth muscle cells. J Urol 1994, 152:1308–1314.
24. Traish AM, Palmer MA, Goldstein I, Moreland RB: Expression of functional musarinic acetylcholine receptor subtypes in cultured human corpus cavernosum and in cultured smooth muscle cells. Receptors 1995, 5:159–176.
25. Stief CG, Noack T, Andersson KE: Signal transduction in cavernous smooth muscle. Wor l d J Ur ol 1997, 15:27–31. DOI: 10.1007/BF01275153
26. Traish AM, Moreland RB, Gallant C, et al.: G-protein-coupled receptor agonists augment adenylyl cyclase activity induced by forskolin in human corpus cavernosum smooth muscle cells. Receptors Signal Transduction 1997, 7:123–134.
27. Kim YC, Davies MG, Lee TH, et al.: Characterization and function of histamine receptors in corpus cavernosum. J Urol 1995, 153:506–510. DOI: 10.1097/00005392-199502000-00072
28. Traish AM, Moreland RB, Huang Y-H, Goldstein I: Expression of functional alpha-2-adrenergic receptor subtypes in human corpus cavernosum and in human corpus caverno-sum smooth muscle cells. Receptors Signal Transduction 1997, 7:55–67.
29. Gupta S, Moreland RB, Daley JT, et al.: Corpus cavernosum smooth muscle expresses functional post-synaptic alpha-2-adrenergic receptors. Br J Pharmacol 1998, 123:1237–1245. DOI: 10.1038/sj.bjp.0701739
30. Cawello W, Schweer H, Dietrich B, et al.: Pharmacokinetics of prostaglandin E1 and its main metabolites after intra-cavernous injection and short-term infusion of prostaglan-din E1 in patients with erectile dysfunction. J Urol 1997, 158:1403–1407. DOI: 10.1016/S0022-5347(01)64226-5
31. Chew KK, Earle CM, Stuckey BGA, Keogh EJ: Penile fibrosis in intracavernosal PGE1 therapy for erectile dysfunction. Int J Impot Res 1997, 9:225–229. DOI: 10.1038/sj.ijir.3900296
32. Earle CM, Chew KK, Stuckey BGA, Keogh EJ: Pain with intrac-avernosal therapy [abstract A62]. Int J Impot Res 1996, 8:114.
33. Sato Y, Suzuki N, Adachi H, et al.: Effect of neurotropin for penile pain induced by intracavernous injection of prostaglandin E1 [abstract D67]. Int J Impot Res 1996, 8:139.
34. Giuliano FA, Rampin O, Benoit G, Jardin A: Neural control of penile erection. Urol Clin North Am 1995, 22:747–766.
35. Kapoor VK, Chahal AS, Jyoti SP, et al.: Intracavernous papervine for impotence in spinal cord injutred patients. Paraplegia 1995, 31:675–680.
36. Hackenburg O, Wetterauer U, Kopperman U, et al.: Systemic pharmacokinectics of papaverine and phentolamine: comparison of intravenous and intracavernous application. Int J Impot Res 1990, 2:247–250.
37. Bechara A, Casabe A, Cheliz G, et al.: Prostaglandin E1 versus micture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J Urol 1996, 155:913–914. DOI: 10.1016/S0022-5347(01)66344-4
38. Martinez-Pineriro L, Lopez-Tello J, Dorrego J: Preliminary results of a comparative study with intracavernous sodium nitroprusside and prostaglandin E1 in patients with erectile dysfunction. J Urol 1995, 153:1487–1490. DOI: 10.1016/S0022-5347(01)67441-X
39. McMahon CG: A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentola-mine mesylate in the treatment of erectile dysfunction. Int J Impot Res 1996, 8:233–236.
40. Gerstenberg TC, Metz P, Otteson B: Intracavernous self-injection with vasoactive intestinal peptide and phentola-mine in the management of erectile failure. J Urol 1992, 147:1277–1279.
41. Mulhall JP, Daller M, Traish AM, et al.: Intracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. J Urol 1997, 158:1752–1758. DOI: 10.1016/S0022-5347(01)64118-1
42. Buvat J, Costa P, Morlier D, et al.: Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorohydrate in chronic organic erectile dysfunction. J Urol 1998, 159:116–119. DOI: 10.1016/S0022-5347(01)64030-8
43. Kaplan SA, Reis RB, Kohn IJ, et al.: Combination therapy using oral apha-blockers and intracavernosal injection in men with erectile dysfunction. Urology 1998, 52:739–743. A recent pilot study using oral ??-blockers and intracavernosal injections in combination therapy. DOI: 10.1016/S0090-4295(98)00388-4